---
title: "Can-Fite’s Namodenoson meets primary safety endpoints in Phase IIa trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291602677.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-07-02T09:22:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291602677.md)
  - [en](https://longbridge.com/en/news/291602677.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291602677.md)
---

# Can-Fite’s Namodenoson meets primary safety endpoints in Phase IIa trial

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [CANF.US](https://longbridge.com/en/quote/CANF.US.md)

## Related News & Research

- [Amgen’s Repatha receives positive CHMP opinion for broader cardiovascular use](https://longbridge.com/en/news/294363759.md)
- [Pfizer seeks label expansion for Litfulo after double Phase III NSV win](https://longbridge.com/en/news/294400212.md)
- [Synlogic and Caldera sign merger agreement](https://longbridge.com/en/news/294331423.md)
- [FDA AdCom shuns Capricor’s DMD cell therapy amid data dispute](https://longbridge.com/en/news/294380808.md)
- [argenx signs agreement to buy Forte Biosciences for $2.2bn](https://longbridge.com/en/news/294040071.md)